Thank you This live web event has ended. Thank you for attending. Contributors Charles (Ken) Stover, MedImmune After obtaining his PhD at the University of Texas, Ken Stover started his postgraduate career at the Walter Reed Army Institute of Research (WRAIR) in Washington D.C. as a Captain in the U.S. Army, where he worked on the molecular biology, pathogenesis and discovery of protective antigens for infectious disease vaccines. Ken joined MedImmune in 1989 where he led efforts to develop a new live-vectored vaccine platform for multiple infectious diseases based on the BCG tuberculosis vaccine. Ken’s efforts in the molecular microbiology of tuberculosis transitioned from vaccine research to small molecule drug discovery in 1993 when he joined Seattle based biotech PathoGenesis to lead their drug discovery efforts for new tuberculosis drugs and investigations into bacterial pathogenesis and drug resistance. At PathoGenesis, a new in vitro-in vivo drug screening strategy led to the identification of a novel antitubercular clinical candidate, PA824 (Pretomanid), now in Phase 3 clinical studies. At PathoGenesis, Ken also directed functional genomic work on Staphylococcus aureus and Pseudomonas aeruginosa and the P. aeruginosa genome project. He joined Pfizer’s Ann Arbor laboratories in 2002 where he directed the Molecular Science’s biology efforts on target validation and antibiotic lead identification until 2007 and Pfizer Animal Health’s platform technology discovery efforts from 2007-2009. Ken returned to MedImmune and the Biologicals field in 2009 to build and lead new antibody discovery efforts focused on the prevention and treatment of serious multidrug-resistant bacterial infections where his team’s efforts to date have generated two clinical candidates, MEDI4893 targeting S. aureus and MEDI3902 targeting P. aeruginosa which are currently in phase 2 human clinical studies.